Key result
Electroconvulsive therapy (ECT) and its regulatory oversight by the FDA are the primary subjects of this publication.
Key points are not available for this paper at this time.
Alerts clinicians to FDA ECT oversight; leaves open cardiovascular safety questions in practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
McDonald et al. (2016) studied this question. Electroconvulsive therapy (ECT) and its regulatory oversight by the FDA are the primary subjects of this publication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: